Evotec AG has entered into a collaboration with Probiodrug AG, a biopharmaceutical company focused on drug development for major age-related diseases. Evotec will set up and validate assays to support preclinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease (AD). Glutaminyl cyclase is a novel enzyme target discovered by Probiodrug, and plays a role in the pathogenesis of AD as well as potentially other diseases.
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are pleased to enter this collaboration with Probiodrug to use our first class assay development capabilities to support the preclinical and clinical development of QC inhibitors in Alzheimer’s disease and other indications. This is a good example of how Evotec can support biotech companies with their specific drug discovery needs.”
Evotec, Probiodrug in Alzheimer’s Assay Alliance
Published November 28, 2012
blog comments powered by Disqus